Agios Pharmaceuticals, Inc.

Equities

AGIO

US00847X1046

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
31.49 ^USD	-0.57%		+6.64%	+41.40%

Feb. 16	RBC Trims Price Target on Agios Pharmaceuticals to $42 From $43, Keeps Outperform Rating	MT
Feb. 15	Agios Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Agios Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023

February 15, 2024 at 07:00 am EST

Agios Pharmaceuticals, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported revenue was USD 26.82 million compared to USD 14.24 million a year ago. Net loss was USD 352.09 million compared to USD 231.8 million a year ago.

Basic loss per share from continuing operations was USD 6.33 compared to USD 4.23 a year ago. Basic loss per share was USD 6.33 compared to USD 4.23 a year ago.

Latest news about Agios Pharmaceuticals, Inc.

RBC Trims Price Target on Agios Pharmaceuticals to $42 From $43, Keeps Outperform Rating	Feb. 16	MT
Agios Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 15	CI
Agios Pharmaceuticals 2023 Loss Widens, Revenue Rises	Feb. 15	MT
Transcript : Agios Pharmaceuticals, Inc., Q4 2023 Earnings Call, Feb 15, 2024	Feb. 15
Agios Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 15	CI
Transcript : Agios Pharmaceuticals, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-10-2024 07:30 AM	Jan. 10
Agios Pharmaceuticals Insider Sold Shares Worth $277,397, According to a Recent SEC Filing	Jan. 09	MT
Agios Pharmaceuticals, Inc. Announces Key Anticipated 2024 Milestones Across Rare Disease Portfolio	Jan. 08	CI
Agios Pharmaceuticals Shares Jump Pre-Bell as Phase 3 Study on Blood Disorder Treatment Meets Endpoints	Jan. 03	MT
Agios' blood disorder drug meets goals of late-stage study	Jan. 03	RE
Agios Pharmaceuticals, Inc. Announces Phase 3 Energize Study of Mitapivat Met Primary Endpoint and Both Key Secondary Endpoints in Adults with Non-Transfusion-Dependent Alpha- or Beta-Thalassemia	Jan. 03	CI
Transcript : Agios Pharmaceuticals, Inc. - Special Call	Jan. 03
Transcript : Agios Pharmaceuticals, Inc. - Special Call	Dec. 11
Agios Pharmaceuticals, Inc. Presents Positive Results from Phase 2 Portion of the Rise Up Pivotal Study in Sickle Cell Disease at 65Th ASH Annual Meeting and Exposition	Dec. 09	CI
Agios Pharmaceuticals, Inc. Announces Clinical Proof-Of-Concept in Phase 2A Trial of AG-946 for the Treatment of Anemia in Lower-Risk Myelodysplastic Syndromes	Nov. 20	CI
Goldman Sachs Adjusts Price Target on Agios Pharmaceuticals to $28 From $32, Maintains Neutral Rating	Nov. 03	MT
Agios Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 02	CI
Transcript : Agios Pharmaceuticals, Inc., Q3 2023 Earnings Call, Nov 02, 2023	Nov. 02
Earnings Flash (AGIO) AGIOS PHARMACEUTICALS Posts Q3 Revenue $7.4M, vs. Street Est of $7.5M	Nov. 02	MT
Transcript : Agios Pharmaceuticals, Inc. Presents at Morgan Stanley 21st Annual Global Healthcare Conference 2023, Sep-12-2023 07:30 AM	23-09-12
Insider Sell: Agios Pharmaceuticals	23-08-21	MT
Insider Sell: Agios Pharmaceuticals	23-08-10	MT
JPMorgan Adjusts Agios Pharmaceuticals' Price Target to $32 From $33, Keeps Neutral Rating	23-08-07	MT
Agios Pharmaceuticals Signs License Deal With Alnylam for Potential Treatment for Rare Blood Disease	23-08-03	MT
Transcript : Agios Pharmaceuticals, Inc., Q2 2023 Earnings Call, Aug 03, 2023	23-08-03

Chart Agios Pharmaceuticals, Inc.

Duration

Period

More charts

Company Profile

Agios Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and delivering transformative therapies for patients living with rare diseases. It markets a first-in-class pyruvate kinase (PK) activator for adults with PK deficiency, the first disease-modifying therapy for debilitating hemolytic anemia. Its lead product candidate in its genetically defined disease (GDD) portfolio, PYRUKYND (Mitapivat), is an activator of both wild-type and a variety of mutant pyruvate kinase (PK) enzymes, for the treatment of hemolytic anemias. The Mitapivat is an orally available small molecule and a potent activator of the pyruvate kinase R (PKR) enzymes. In addition, it is also evaluating mitapivat for the treatment of alpha- and beta- thalassemia and sickle cell disease (SCD) in ongoing clinical trials. The Company is also developing AG-946, a clinical-stage oral activator of PKR enzymes for the treatment of hemolytic anemias and other indications, including SCD.

Sector

Biotechnology & Medical Research

Calendar

2024-05-02 - Q1 2024 Earnings Release

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Agios Pharmaceuticals, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

31.49 USD

Average target price

40.67 USD

Spread / Average Target

+29.14%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
AGIOS PHARMACEUTICALS, INC.	+41.40%	1.77B
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.74B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs